InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,607.60
(
-0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.30
(
-0.69%
)
Bitcoin
62,471.53
(
0.22%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

zuize

Send PM Follow Ignore
Followers 6
Posts 461
Boards Moderated 0
Alias Born 11/13/2013

zuize

Re: None

Monday, 07/28/2014 6:29:14 PM

Monday, July 28, 2014 6:29:14 PM

Post# of 80490


AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
28/07/2014
AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).
Link to the full article: AstraZeneca and Roche announce partnership to develop AZD9291



My understanding is that if AstraZeneca succeed with AZD9291, it will overtake Roche's Tarceva as first line drug for NSCLC and become a huge threat to Roche's future revenue, then why would they be willing to help AstraZenenca with AZD9291 development?
I wonder if the Roche is aware of the study conducted by the folks at Genentech on the combination of Tarceva + Ponatinib for addressing mutation issue? Thanks!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up